Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000

Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancerNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health conditions related to life-altering diseases, today announces that the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration (FDA) regarding its Invest

Related Keywords

Canada ,Jan Anders Karlsson ,Laurie Doyle ,Pharmaceuticals Inc ,Filament Health Corp ,Drug Administration ,Mc Services ,Reset Pharma ,Investigational New Drug ,Reset Pharmaceuticals ,Demoralization Syndrome ,Scientific Advisory Board ,Strategic Advisory Board ,Reset Pharmaceutical ,Cancer ,Demoralization ,The Company ,Mental Health Conditions ,Product Candidate ,Company ,